Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Q1 FY24 Earnings Presentation
17 slides from Aurobindo Pharma's earnings presentation, Aug 12, 2023
Slide 1: Letter to stock exchanges: Investor / Analysts Presentation
August 12, 2023 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Phiroz Jeejeebhoy Towers, MUMBAI -400 051 25th floor, Dalal Street, MUMBAI -400 001 Company Code No. AUROPHARMA Company
Slide 2: Aurobindo Pharma Limited Earnings Presentation Q1FY24
Aurobindo Pharma Limited Earnings Presentation Q1FY24
Slide 3: Disclaimer
Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma Limited, nor shall it, or any par
Slide 4: Table of Contents
Table of Contents 04 Q1FY24 Business & Financial Highlights 10 Financial Performance 13 Filings Snapshot 3
Slide 5: Q1FY24 Business & Financial Highlights
Q1FY24 Business & Financial Highlights 4
Slide 6: Quarterly Performance – Q1FY24
Quarterly Performance – Q1FY24 Revenue (Rs Crore) US Revenue (US$ Mn) 6,851 386 366 370 402 363 6,407 6,473 331 6,236 5,809 5,739 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 EBITDA (Rs Crore) Net Debt to Equity* 1,151 974 965 954 1,002 837 -0.05 -0.06 -0.06 -0
Slide 7: Consolidated Financial & Business Highlights – Q1FY24
Consolidated Financial & Business Highlights – Q1FY24 Revenue from operations at Rs 6,851 crore, an increase of 9.9% YoY, US revenues at US$ 402 Million Research & Development (R&D) spend at Rs 388 crore in Q1FY24, 5.7% of revenue Vs. Rs. 411 crore in Q4FY23, 6.3% of revenue EBITDA before Forex and
Slide 8: Consolidated Operational Performance
Consolidated Operational Performance Amount (Rs Cr) Q1FY24 Q1FY23 % Change YoY Q4FY23 % Change QoQ Formulations USA 3,304 2,971 11.2% 3,045 8.5% Europe 1,837 1,548 18.6% 1,660 10.6% Growth Markets* 486 431 12.9% 592 -17.9% ARV 190 380 -49.9% 159 19.6% Total Formulations 5,817 5,329 9.2% 5,456 6.6% A
Slide 9: US Business Performance Highlights
US Business Performance Highlights Revenue (Rs Crore) US Formulations • US revenue in Q1FY24 increased by 11.2% YoY and 8.5% QoQ 3,304 2,971 3,045 to Rs. 3,304 crores, accounting for 48.2% of consolidated revenue • Eugia revenue in the US which includes generic injectables & specialty OSD, was US$ 9
Slide 10: Europe, ARV, Growth Markets, API Business Revenues & Performance Highlights
Europe, ARV, Growth Markets, API Business Revenues & Performance Highlights Europe (Rs Crore) Growth Markets (Rs Crore) ARV (Rs Crore) API (Rs Crore) 1,033 1,017 1,837 592 380 1,660 486 1,548 431 906 190 159 Q1FY23 Q4FY23 Q1FY24 Q1FY23 Q4FY23 Q1FY24 Q1FY23 Q4FY23 Q1FY24 Q1FY23 Q4FY23 Q1FY24 Growth M
Slide 11: Financial Summary
Financial Summary 10
Slide 12: Consolidated Profit & Loss Statement (as reported)
Consolidated Profit & Loss Statement (as reported) Rs Cr Q1FY24 Q1FY23 YoY Chg. (%) Q4FY23 QoQ Chg. (%) Revenue from operations 6,850.5 6,235.9 9.9% 6,473.0 5.8% Gross Profit 3,695.8 3,349.2 10.3% 3,542.0 4.3% Gross Margin 53.9% 53.7% 24 bps 54.7% -77 bps Overheads 2,544.4 2,384.5 6.7% 2,539.8 0.2%
Slide 13: Debt profile
Debt profile Jun-23 Forex Loan (US$ Mn) Debt as on (Rs Cr) Mar-20 Mar-21 Mar-22 Mar-23 (3-Months) Closing Rate (INR/USD) 75.665 73.110 75.793 82.170 82.042 732 674 313 592 645 Fx Loan restated 5,549 4,929 2,223 4,638 5,287 Rupee Loan 16.9 43.6 150.1 224.0 3.9 Gross Debt 5,566 4,972 2,373 4,862 5,291
Slide 14: Filing Status
Filing Status 13
Slide 15: US ANDA Filings Snapshot as on 30th June 2023
US ANDA Filings Snapshot as on 30th June 2023 ANDA Filings Addressable Market Therapy ANDAs Size (US$ Bn)^ CNS 140 25.3 Aurobindo (Excl. Eugia Pharma Eugia Pharma Specialty Group 700 613 460 153 500 180 600 450 160 ARV** 38 0.6 Specialty Group) 400 500 140 350 120 400 300 100 62 40.0 250 CVS 109 300
Slide 16: Global regulatory filing Details
Global regulatory filing Details As at As at As at As at As at As at As at As at As at Category Geography Approvals Mar 16 Mar 17 Mar 18 Mar 19 Mar 20 Mar 21 Mar 22 Mar 23 Jun 23 US* 398 429 478 541 586 639 727^ 774^ 814^ (FA: 613, TA:34) Europe** 2,224 2,521 2,848 3,003 3,214 3,374 3,580 3,751 3,79
Slide 17: Thank You
Thank You Digitally signed by ADIREDDY BADDIGAM Date: 2023.08.12 18:24:18 +05'30' For more information, contact: [email protected] Investor Relations | Corporate Communications www.aurobindo.com +91 40 6672 5401 16